GSK Egypt sees surge in 9M-22 consolidated profits

Reuters Images

In 9M-22, GSK Egypt logged standalone net profits after tax worth $37.79 million

Staff Writer, Mubasher

November 30, 2022

PHOTO

GlaxoSmithKline (GSK Egypt) logged EGP 920.72 million in consolidated net profits in the first nine months (9M) of 2022, compared to EGP 70.11 million in the prior-year period.

The company’s sales amounted to EGP 1.16 billion during the January-September 2022 period, a surge from EGP 630.47 million in the corresponding period in 2021, according to a bourse statement on Wednesday.

In 9M-22, GSK Egypt logged standalone net profits after tax worth EGP 929.74 million, higher than EGP 89.83 million in 9M-21.

In the first half (H1) of 2022, GSK Egypt witnessed a hike in consolidated net profit to EGP 871.81 million, compared to EGP 20.65 million in H1-21.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.